SAGA Diagnostics raises SEK 106 million (€10.5 million) to accelerate commercialization of ultrasensitive cancer liquid biopsies |
| June 29, 2021 | June 2021 Bond Updates |
|
LUND, Sweden and STOCKHOLM, June 29, 2021 /PRNewswire/ -- SAGA Diagnostics AB ("SAGA"), a cancer liquid biopsy and genomic testing company, today announced that it has raised SEK 106 million (€10.5 million) in a Series A2 financing from both existing and new investors. The Series A2 round... |
| View more at: https://www.prnewswire.com:443/news-releases/saga-diagnostics-raises-sek-106-million-10-5-million-to-accelerate-commercialization-of-ultrasensitive-cancer-liquid-biopsies-301321603.html |
| Related News |